Periorbital muscle atrophy associated with topical bimatoprost therapy

Código QR

Periorbital muscle atrophy associated with topical bimatoprost therapy

Priscilla Xinhui Wang, Victor Teck Chang Koh, Jin Fong ChengDepartment of Ophthalmology, National University Health System, SingaporeAbstract: Topical Bimatoprost is a common and popular prostaglandin analog used as an ocular hypotensive agent in the treatment of glaucoma. Side effects include ocul...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang PX, Koh VT, Cheng JF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/14eac15c4d014f6d844f547c0c2375fd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Abayomi B Ogundele, et al.
Publicado: (2010)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin J-E, et al.
Publicado: (2011)

Periorbital edema secondary to imatinib mesylate
por: Collin M McClelland, et al.
Publicado: (2010)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
por: Campbell JH, et al.
Publicado: (2014)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
por: Scott D Smid
Publicado: (2009)

Bimatoprost in the treatment of eyelash hypotrichosis
por: Simon K Law
Publicado: (2010)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee A, et al.
Publicado: (2013)

Nonselective &szlig;-blocker propranolol for orbital and periorbital hemangiomas in infants: a new first-line of treatment?
por: El-Essawy R, et al.
Publicado: (2011)

Topical intraocular pressure therapy effects on pregnancy
por: Mendez-Hernandez C, et al.
Publicado: (2012)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
por: Inoue K, et al.
Publicado: (2012)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue K, et al.
Publicado: (2014)

An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan® RC Early Analysis Review (CLEAR) trial
por: Crichton AC, et al.
Publicado: (2014)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Moataz E Gheith, et al.
Publicado: (2008)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Antoine Lafuma, et al.
Publicado: (2011)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober D, et al.
Publicado: (2015)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura T, et al.
Publicado: (2012)

Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment
por: Gerrett Brief, et al.
Publicado: (2010)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Potential role of lampalizumab for treatment of geographic atrophy
por: Rhoades W, et al.
Publicado: (2015)

Potential role of lampalizumab for treatment of geographic atrophy [Retraction]
por: Rhoades W, et al.
Publicado: (2015)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
por: Shen J, et al.
Publicado: (2018)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
por: Maruyama Y, et al.
Publicado: (2015)

Iritis and iris atrophy after eyebrow epilation with alexandrite laser
por: Elkin Z, et al.
Publicado: (2011)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Laube T, et al.
Publicado: (2012)

Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
por: Higashiyama T, et al.
Publicado: (2018)

Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration
por: Pukhraj Rishi, et al.
Publicado: (2011)

Association between a relative afferent pupillary defect using pupillography and inner retinal atrophy in optic nerve disease
por: Takizawa G, et al.
Publicado: (2015)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers JS, et al.
Publicado: (2014)

The role of clinical parapapillary atrophy evaluation in the diagnosis of open angle glaucoma
por: Joshua R Ehrlich, et al.
Publicado: (2010)

An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
por: Borchert M, et al.
Publicado: (2016)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee D, et al.
Publicado: (2017)

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study
por: Gutierrez-Diaz E, et al.
Publicado: (2014)

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
por: E Randy Craven, et al.
Publicado: (2010)

Choroidal atrophy in a patient with paraneoplastic retinopathy and anti-TRPM1 antibody
por: Ueno S, et al.
Publicado: (2014)

Retinitis pigmentosa with concomitant essential iris atrophy and glaucoma – case report
por: Meirelles SH, et al.
Publicado: (2015)

An observational study of bimatoprost 0.01% in treatment-na&iuml;ve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
por: Nixon DR, et al.
Publicado: (2012)

Topical azithromycin or ofloxacin for endophthalmitis
por: Stewart ML, et al.
Publicado: (2012)

Ultrawide-field fundus photography of the first reported case of gyrate atrophy from Australia
por: Moloney TP, et al.
Publicado: (2014)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
por: Abayomi B Ogundele, et al.
Publicado: (2010)